Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRE-LD: Low-dose vs Standard-dose Aspirin Post-PCI
NCT07846462Recruiting
- Sponsor
- Jilin University
- Start
- Mar 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Randomised, open-label trial of aspirin in acute coronary syndrome (ACS) and Chronic Coronary Syndrome (CCS) (2 arms), sponsored by Jilin University. Primary endpoint: Major Adverse Cardiac and Cerebrovascular Events at 12 months. Started Mar 2026; status: recruiting.
02
Drugs
aspirin
03
Conditions
acute coronary syndrome (ACS)Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on NCT07846462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07846462.